Use of phytocanabinoids in animal models of Parkinson's disease: Systematic review

被引:0
|
作者
Alves, Amanda de Deus Ferreira [1 ]
Dias, Fernanda Carolina Ribeiro [1 ,2 ]
Cadena, Pabyton Gonsalves [3 ]
Silva-Jr, Valdemiro Amaro [1 ]
机构
[1] Univ Fed Rural Pernambuco, Dept Vet Med, Pernambuco, Brazil
[2] Univ Fed Triangulo Mineiro, Inst Biol & Nat Sci, Cellular Interact Lab, Uberaba, MG, Brazil
[3] Univ Fed Rural Pernambuco, Dept Morphol & Anim Physiol, Recife, Brazil
关键词
Dopaminergic neurons; Cannabis; Cannabidiol; Delta-9-tetrahydrocannabinol; 6-hydroxydopamine; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; RAT MODEL; CANNABIDIOL; ACTIVATION; CATALEPSY; 6-OHDA; MICE;
D O I
10.1016/j.neuro.2024.08.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This systematic review was carried out with the aim of evaluating the use of medicinal Cannabis for the treatment of Parkinson's disease in experimental models. Furthermore, we sought to understand the main intracellular mechanisms capable of promoting the effects of phytocannabinoids on motor disorders, neurodegeneration, neuroinflammation and oxidative stress. The experimental models were developed in mice, rats and marmosets. There was a predominance of using only males in relation to females; in three studies, the authors evaluated treatments in males and females. Drugs were used as inducers of Parkinson's disease: 6-hydroxydopamine (6OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), lipopolysaccharide (LPS), and rotenone. Substances capable of promoting catalepsy in animals were also used: haloperidol, L-nitro-N-arginine (L-NOARG), WIN55,212-2, and reserpine. The inducing agent was injected stereotaxically or intraperitoneally. The most commonly used treatments were cannabidiol (CBD), Delta-9-tetrahydrocannabinol (Delta-9 THC) and Delta-9tetrahydrocannabivarin (Delta-9 THCV), administered intraperitoneally, orally, subcutaneously and intramuscularly. The use of phytocannabinoids improved locomotor activity and involuntary movement and reduced catalepsy. There was an improvement in the evaluation of dopaminergic neurons, while in relation to dopamine content, the treatment had no effect. Inflammation, microglial/astrocyte activation and oxidative stress were reduced after treatment with phytocannabinoids, the same was observed in the results of tests for allodynia and hyperalgesia.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [11] Animal Models for Parkinson's Disease
    Patil, Dilip A.
    Patil, Vishal A.
    Bari, Sanjay B.
    Surana, Sanjay J.
    Patil, Pravin O.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (09) : 1580 - 1594
  • [12] Use of viral vectors to create animal models for Parkinson's disease
    Loew, Karin
    Aebischer, Patrick
    NEUROBIOLOGY OF DISEASE, 2012, 48 (02) : 189 - 201
  • [13] Lipopolysaccharide Animal Models for Parkinson's Disease
    Liu, Mei
    Bing, Guoying
    PARKINSONS DISEASE, 2011, 2011
  • [14] Animal models of neurodegeneration in Parkinson's disease
    Earl, C
    Sautter, J
    PARKINSON'S DISEASE, 2002, 1 : 88 - 93
  • [15] Animal models of Parkinson's disease and their applications
    Park, Hyun Jin
    Zhao, Ting Ting
    Lee, Myung Koo
    JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME, 2016, 6
  • [16] Animal models of Parkinson's disease progression
    Meredith, Gloria E.
    Sonsalla, Patricia K.
    Chesselet, Marie-Francoise
    ACTA NEUROPATHOLOGICA, 2008, 115 (04) : 385 - 398
  • [17] New animal models for Parkinson's disease
    Dawson, TM
    CELL, 2000, 101 (02) : 115 - 118
  • [18] Animal Models of Parkinson's Disease 2012
    Imai, Yuzuru
    Venderova, Katerina
    Lim, Kah-Leong
    PARKINSONS DISEASE, 2012, 2012
  • [19] Inflammatory Animal Models of Parkinson's Disease
    Garcia-Revilla, Juan
    Herrera, Antonio J.
    de Pablos, Rocio M.
    Luis Venero, Jose
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 : S165 - S182
  • [20] Animal Models of Parkinson's Disease: Are They Useful or Not?
    Barker, Roger A.
    Bjorklund, Anders
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 (04) : 1335 - 1342